Applications of (S)-2-Benzyloxycarbonylamino-Pentanedioic Acid 5-Benzyl Ester in Industrial Manufacturing

Our advanced production of (S)-2-Benzyloxycarbonylamino-Pentanedioic Acid 5-Benzyl Ester serves specialized roles across high-value pharmaceutical and fine chemical industrial sectors. As a key protected intermediate, this chiral compound contributes to downstream syntheses requiring precision and regulatory compliance. Below we detail verified industrial applications across select market areas, focusing on technical differentiation based on real-world product integration.

1. Peptide Drug Intermediate Manufacturing

In peptide synthesis for active pharmaceutical ingredient (API) production, this compound acts as a crucial fragment during stepwise solid-phase or solution-phase assembly of complex peptides. It provides protected carboxyl and amine groups, allowing selective deprotection without racemization, which is vital in maintaining stereochemical integrity in advanced peptide products.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II (APIs)
• US FDA cGMP 21 CFR Part 211
• Relevant USP, EP, and JP monographs for peptide APIs

Typical usage ratio

• Typically incorporated at 1.0–1.3 molar equivalents per protected amino acid coupling step, adjusted for peptide chain length and resin capacity

Downstream process integration

• Added during protected amino acid coupling cycles on solid supports or in solution-phase synthesis; follows with selective deprotection and activation prior to peptide elongation

Final product types

• Synthetic peptide APIs such as gonadorelin analogs, somatostatin mimetics, and novel peptide drug candidates

2. Chiral Building Block for Prodrug Synthesis

Pharmaceutical manufacturers use this protected glutamic acid derivative as a stereodefined building block for synthesizing prodrugs that require precise spatial orientation and metabolic stability modulation. Its benzyl ester moiety enables controlled ester hydrolysis in later stages, facilitating regulated prodrug activation profiles in the finished formulation.

Industry compliance standards

• US FDA Guidance for Industry: Prodrugs
• EMA Guideline on the Pharmacokinetic and Clinical Evaluation of Modified-Release Dosage Forms
• European Pharmacopoeia section 2.4.19 for chiral impurities
• ISO 9001:2015 for quality management in fine chemical manufacturing

Typical usage ratio

• Deployed at 0.9–1.1 equivalents relative to nucleophilic reactant, with final ratio adjusted according to desired prodrug structure and conversion efficiency

Downstream process integration

• Entered at the pre-assembly stage of side chain-modified APIs, following initial derivatization and chiral auxiliary removal; undergoes selective deprotection and subsequent conjugation to active payloads

Final product types

• Oral and injectable prodrugs for oncology, CNS, and antiviral therapy, including glutamate conjugates and depot-formulation APIs

3. D-Amino Acid Derivative Synthesis in Fine Chemicals

Contract manufacturing organizations and specialty chemical producers employ this intermediate for creating advanced D-amino acid derivatives needed in asymmetric synthesis and catalog reagent businesses. The benzyl-protected form enables regioselective transformations, protection switching, and subsequent downstream amidation or esterification processes under controlled reaction parameters.

Industry compliance standards

• ISO 13485:2016 where derivatives are used in medical-grade or diagnostic reagent environments
• REACH Regulation (EC) No 1907/2006 for chemical substances
• EcoVadis CSR audits for specialty chemical production
• In-house analytical and chiral purity specifications validated per GLP

Typical usage ratio

• Loaded at 10–30% total mass fraction in multi-step fine chemical syntheses, with precise adjustments made for the desired chiral purity and final product configuration

Downstream process integration

• Incorporated at initial or intermediate stage protection/deprotection sequences, followed by asymmetric catalysis or coupling to introduce functional side chains

Final product types

• D-configured amino ester derivatives, building blocks for chiral stationary phases, and advanced reagents for pharmaceutical and diagnostic R&D

4. Key Intermediate for Anticancer API Development

Oncology-focused pharmaceutical API manufacturers select this protected glutamic acid for targeted linker or payload synthesis, especially in the preparation of antibody-drug conjugate (ADC) intermediates where steric selectivity and controlled release determine drug safety and efficacy. Its dual protection profile fosters sequential functionalization prior to assembly into cytotoxic payloads or linker units.

Industry compliance standards

• US Pharmacopeia (USP) General Chapter <797> for sterile pharmaceutical compounding components
• Good Laboratory Practice (GLP) for intermediate qualification stages
• Japanese Pharmaceutical Raw Materials Standards (JP)
• Specific oncology API monograph standards per EMA and FDA

Typical usage ratio

• Incorporated at 0.8–1.2 equivalents per linker or hydrolysable group, with scale determined by targeted ADC batch size and linkage density requirements

Downstream process integration

• Utilized in protected coupling steps for linker assembly, with subsequent deprotection and payload attachment conducted under controlled inert conditions to prevent cross-reaction

Final product types

• Protected or partially deprotected intermediates for ADC payloads and targeted anticancer cytotoxins

5. Stereoselective Synthesis of CNS Drug Candidates

Research-driven pharmaceutical manufacturers deploy this intermediate as a chiral template in the stepwise assembly of central nervous system (CNS) drug molecules that demand strict isomeric purity. Its carboxyl and amine protection patterns reduce unwanted side reactions, supporting enantioselective alkylation, amidation, or cyclization strategies for small molecule CNS therapeutics.

Industry compliance standards

• FDA 21 CFR Part 314 (NDA/ANDA submissions for CNS APIs)
• cGMP for investigational new drug (IND) substance production
• Pharmacopoeial guidelines for chiral purity (USP, EP, JP)
• ICH Q3A/B for residual solvents and impurities

Typical usage ratio

• Applied at 1.0–1.5 molar equivalents in selective intermediate formation, optimized by route-specific yield and desired CNS-active compound configuration

Downstream process integration

• Engaged during enantioselective build-up of CNS drug candidates, beginning at the protected fragment condensation stage and followed by sequence-specific modification and subsequent deprotection

Final product types

• Enantiomerically pure CNS drug intermediates, including anticonvulsant and neuroprotective agent scaffolds